Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Cell | Dec 1, 2016

Therapeutic blocking of the PD1 pathway results in significant tumor responses, but resistance is common. We demonstrate that prolonged interferon signaling orchestrates PDL1-dependent and PDL1-independent resistance to immune checkpoint blockade (ICB) and to combinations such as radiation plus anti-CTLA4. Persistent type II interferon signaling allows tumors to acquire STAT1-related epigenomic changes and augments expression of interferon-stimulated genes and ligands for multiple T cell inhibitory receptors. Both type I and II interferons maintain this resistance program. Crippling the program genetically or pharmacologically interferes with multiple inhibitory pathways and expands distinct T cell populations with improved function despite expressing markers of severe exhaustion. Consequently, tumors resistant to multi-agent ICB are rendered responsive to ICB monotherapy. Finally, we observe that biomarkers for interferon-driven resistance associate with clinical progression after anti-PD1 therapy. Thus, the duration of tumor interferon signaling augments adaptive resistance and inhibition of the interferon response bypasses requirements for combinatorial ICB therapies.

Pubmed ID: 27912061 RIS Download

Mesh terms: Animals | B7-H1 Antigen | CTLA-4 Antigen | Cell Line, Tumor | Drug Resistance, Neoplasm | Heterografts | Humans | Interferons | Melanoma | Mice | Neoplasm Transplantation | Radioimmunotherapy | STAT1 Transcription Factor | T-Lymphocytes

Research resources used in this publication

Research tools detected in this publication

Data used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, Id: R01 CA163739
  • Agency: NIAID NIH HHS, Id: U19 AI082630
  • Agency: NIAID NIH HHS, Id: P01 AI112521
  • Agency: NCI NIH HHS, Id: P50 CA174523
  • Agency: NCI NIH HHS, Id: R01 CA158186
  • Agency: NCI NIH HHS, Id: P30 CA016520
  • Agency: NIAID NIH HHS, Id: R01 AI105343
  • Agency: NIAID NIH HHS, Id: U01 AI095608
  • Agency: NCI NIH HHS, Id: R01 CA172651

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

R Project for Statistical Computing

Software environment and programming language for statistical computing and graphics that provides a wide variety of statistical (linear and nonlinear modelling, classical statistical tests, time-series analysis, classification, clustering, etc) and graphical techniques. R is an integrated suite of software facilities for data manipulation, calculation and graphical display.


View all literature mentions


A toolkit for processing next-gen sequencing data. These programs were also implemented in Bioconductor R package Rsubread.


View all literature mentions


Java toolset for working with next generation sequencing data in the BAM format.


View all literature mentions


A network of ftp and web servers around the world that store identical, up-to-date, versions of code and documentation for R.


View all literature mentions